Navigation Links
iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board
Date:6/11/2009

SOUTH SAN FRANCISCO, Calif., June 11 /PRNewswire/ -- iZumi Bio, Inc., a biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells, today announced the appointment of Corey S. Goodman, Ph.D., to the company's board of directors and scientific advisory board. Dr. Goodman most recently served as president of Pfizer's Biotherapeutics and Bioinnovation Center.

"Dr. Goodman's drug discovery and development expertise will be instrumental as we apply our iPS technology to the development of new therapeutics for unmet medical needs. We will look to Dr. Goodman's extensive knowledge and leadership in neurology to help advance our proprietary neurodegenerative programs in amyotrophic lateral sclerosis, spinal muscular atrophy and Parkinson's disease," said John P. Walker, chief executive officer of iZumi. "Over the next few months, we intend to build a world-renowned scientific advisory board, in order to provide guidance and scientific direction for both our proprietary neurodegenerative programs and for additional disease areas, such as metabolic disease, that we plan to pursue through partnerships."

"iZumi's approach opens a new door for stem cell research and its application to therapeutic discovery, and I am excited to work with the company to identify new treatment options for patients suffering from difficult-to-treat conditions including neurodegenerative diseases," said Dr. Goodman.

Prior to joining Pfizer, Dr. Goodman served as the president and chief executive officer of Renovis from 2001 until 2007, when the company merged with Evotec. He has advised numerous biotechnology companies, and co-founded two companies, including Exelixis and Renovis.

Dr. Goodman was a professor at Stanford University and the '/>"/>

SOURCE iZumi Bio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development
2. iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer
3. iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
4. The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease
5. NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Companys Audit Committee
6. Bionovo Appoints Dr. Klaus Kohl as Chief Technical Officer
7. PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations
8. SIRO Group Appoints Scott L. Spector as President, Strategic Operations, for its European Business
9. China Sky One Medical, Inc. Appoints Pricewaterhouse Coopers to Help Develop a SOX 404 Compliance Program
10. Simcere Pharmaceutical Group Appoints Dr. Peng Wang as Chief Scientific Officer
11. Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015 Oxford Finance LLC ("Oxford"), a ... sciences and healthcare services companies, today announced the closing ... with Celula, Inc., a diagnostic testing company focused on ... patient care and improved outcomes.  Proceeds of the loan ... the commercialization of its products in the U.S. and ...
(Date:4/30/2015)... April 30, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, today announced that it will release ... 7, 2015 after the close of the U.S. financial ... webcast on Thursday, May 7, 2015 at 4:30 p.m. ... and recent corporate developments. For both "listen-only" ...
(Date:4/30/2015)... SureClinical, a leader in cloud-based health ... joined SureClinical’s executive team as Chief Financial Officer. ... executive with over 25 years in leadership roles ranging ... Ms. Morris joins SureClinical from Marrone Bio Innovations (MBI), ... of MBI from its founding in 2006 until 2011, ...
(Date:4/29/2015)... (TSX-V: BRM) ("Biorem" or "the Company") today announced its results for the ... year-end financial statements and MD&A have been filed on SEDAR ( www.sedar.com ... 2014 , 2013 Revenue 3,968 , 5,121 ... , 1,703 , 2,231 , 5,866 Operating  ... , 4,562 Ebitda* 92 , 418 , ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Julie I. Morris Joins SureClinical as Chief Financial Officer 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4
... EXTON, Pa., Feb. 28, 2012 ViroPharma Incorporated (Nasdaq: ... fourth quarter and year ended December 31, 2011. ... in annual net product sales, including $251 million in net ... in net sales of Vancocin® (Vancomycin Hydrochloride Capsules, USP); ...
... NOVATO, Calif., Feb. 28, 2012 Ultragenyx Pharmaceutical ... for rare and ultra-rare genetic disorders, today announced ... has granted orphan drug designation for UX003 for ... an extremely rare autosomal recessive lysosomal storage disorder ...
... Verenium Corporation (Nasdaq: VRNM ), a leading ... high-performance enzymes, today announced that it will release ... 5, 2012 at 8:00 a.m. ET. In conjunction with the ... webcast on Monday, March 5 at 8:30 a.m. ET. ...
Cached Biology Technology:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 12Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 2Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 3Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results 2Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results 3
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and Markets ... "Face and Voice Biometrics - Global Strategic Business Report" report ... for Face and Voice Biometrics in US$ Thousands by the following ... analytics for the US, Canada , ... , Middle East & ...
(Date:3/23/2015)... -- SoundView Technology Group issues a new research update following ... smart wallet. SoundView was one of the selected user groups to ... Wocket in multiple scenarios and outlets. Soundview ... making both debit and credit card payments.  ... company meets their plans in 2015, it would push our ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... of Appeals has overturned an August 2010 ban on federal ... broader exploration of how stem cells function and how they ... incurable diseases. The ruling has been welcomed by the ... and by the nation,s top researchers in the field, including ...
... 27, 2011 According to the Centers for Disease Control ... more likely to die from diabetes than someone living in ... parts of the United States. Now, a group of seven ... change those health disparities and improve health through the creation ...
... A gene therapy approach using a protein called ... of age-related macular degeneration (AMD), according to a new ... of Medicine. Led by senior author Rajendra Kumar-Singh, PhD, ... delivered by a gene therapy approach significantly reduced the ...
Cached Biology News:US Appeals Court opens federal funding for stem cell research 2Network created to address obesity, chronic health issues in Appalachian region 2Network created to address obesity, chronic health issues in Appalachian region 3Gene therapy shows promise against age-related macular degeneration 2
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: